Jaguar Health Begins Trial for Crofelemer in Treating Rare Diseases

Jaguar Health, Inc. has commenced dosing the first patient in a trial exploring crofelemer as a treatment for Microvillus Inclusion Disease (MVID) in pediatric patients. The trial, led by Dr. Mohamad Miqdady at Sheikh Khalifa Medical City in the UAE, will also include those with Short Bowel Syndrome with Intestinal Failure (SBS-IF).

Crofelemer, a plant-based drug by Jaguar, holds Orphan Drug Designation from both the FDA and the European Medicines Agency for MVID and SBS-IF. The trial may yield Proof-of-Concept (POC) data by mid-2025, potentially allowing early patient access in certain European countries. MVID and SBS-IF are severe conditions requiring intensive care. MVID is a rare disease with no approved treatments, while SBS-IF affects thousands worldwide.